Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome
Identifieur interne : 006488 ( Main/Merge ); précédent : 006487; suivant : 006489Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome
Auteurs : Willibald Gerschlager [Royaume-Uni] ; Peter Brown [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-05.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Immunoglobulins, Intravenous.
- drug therapy : Stiff-Person Syndrome.
- psychology : Stiff-Person Syndrome.
- Aged, Female, Humans, Male, Middle Aged, Quality of Life, Questionnaires, Time Factors, Treatment Outcome.
Abstract
The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff‐person syndrome (SPS) have been described exclusively in case reports or open‐label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF‐36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF‐36 subscores for pain, social functioning, general mental health, and energy–vitality with treatment. The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10043
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003056
- to stream Istex, to step Curation: 003056
- to stream Istex, to step Checkpoint: 002D74
- to stream PubMed, to step Corpus: 003A46
- to stream PubMed, to step Curation: 003A46
- to stream PubMed, to step Checkpoint: 003B09
- to stream Ncbi, to step Merge: 000805
- to stream Ncbi, to step Curation: 000805
- to stream Ncbi, to step Checkpoint: 000805
Links to Exploration step
ISTEX:68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10043</idno><idno type="url">https://api.istex.fr/document/68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003056</idno><idno type="wicri:Area/Istex/Curation">003056</idno><idno type="wicri:Area/Istex/Checkpoint">002D74</idno><idno type="wicri:doubleKey">0885-3185:2002:Gerschlager W:effect:of:treatment</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12112212</idno><idno type="wicri:Area/PubMed/Corpus">003A46</idno><idno type="wicri:Area/PubMed/Curation">003A46</idno><idno type="wicri:Area/PubMed/Checkpoint">003B09</idno><idno type="wicri:Area/Ncbi/Merge">000805</idno><idno type="wicri:Area/Ncbi/Curation">000805</idno><idno type="wicri:Area/Ncbi/Checkpoint">000805</idno><idno type="wicri:doubleKey">0885-3185:2002:Gerschlager W:effect:of:treatment</idno><idno type="wicri:Area/Main/Merge">006488</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-05">2002-05</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="590">590</biblScope><biblScope unit="page" to="593">593</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF</idno><idno type="DOI">10.1002/mds.10043</idno><idno type="ArticleID">MDS10043</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Questionnaires</term><term>Stiff-Person Syndrome (drug therapy)</term><term>Stiff-Person Syndrome (psychology)</term><term>Time Factors</term><term>Treatment Outcome</term><term>quality of life</term><term>stiff‐person syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Stiff-Person Syndrome</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Stiff-Person Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff‐person syndrome (SPS) have been described exclusively in case reports or open‐label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF‐36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF‐36 subscores for pain, social functioning, general mental health, and energy–vitality with treatment. The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS. © 2002 Movement Disorder Society.</div></front></TEI><double doi="10.1002/mds.10043"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10043</idno><idno type="url">https://api.istex.fr/document/68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003056</idno><idno type="wicri:Area/Istex/Curation">003056</idno><idno type="wicri:Area/Istex/Checkpoint">002D74</idno><idno type="wicri:doubleKey">0885-3185:2002:Gerschlager W:effect:of:treatment</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-05">2002-05</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="590">590</biblScope><biblScope unit="page" to="593">593</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF</idno><idno type="DOI">10.1002/mds.10043</idno><idno type="ArticleID">MDS10043</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>quality of life</term><term>stiff‐person syndrome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff‐person syndrome (SPS) have been described exclusively in case reports or open‐label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF‐36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF‐36 subscores for pain, social functioning, general mental health, and energy–vitality with treatment. The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS. © 2002 Movement Disorder Society.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome.</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12112212</idno><idno type="pmid">12112212</idno><idno type="doi">10.1002/mds.10043</idno><idno type="wicri:Area/PubMed/Corpus">003A46</idno><idno type="wicri:Area/PubMed/Curation">003A46</idno><idno type="wicri:Area/PubMed/Checkpoint">003B09</idno><idno type="wicri:Area/Ncbi/Merge">000805</idno><idno type="wicri:Area/Ncbi/Curation">000805</idno><idno type="wicri:Area/Ncbi/Checkpoint">000805</idno><idno type="wicri:doubleKey">0885-3185:2002:Gerschlager W:effect:of:treatment</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome.</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Questionnaires</term><term>Stiff-Person Syndrome (drug therapy)</term><term>Stiff-Person Syndrome (psychology)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Stiff-Person Syndrome</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Stiff-Person Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy-vitality with treatment. The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006488 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006488 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:68F355E2DBB9F74B3D0D4C3068DC6FA284A6A6AF
|texte= Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff‐person syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |